New York, NY — November 19, 2025 — HITLAB is expanding its annual Fall Innovators Summit with a new slate of programming aimed at audiences hungry for substantive, expert-led discussions on the forces reshaping healthcare.

When the Summit convenes December 2–4 in New York City, attendees will have access to six standalone half-day symposia—each examining a high-impact area where science, technology, and policy are intersecting at speed.

The new tracks run alongside the main-stage event and feature senior executives and researchers from Takeda, Merck, Pfizer, Genentech, GE Healthcare, Microsoft, Aetna, Memorial Sloan Kettering, Mount Sinai, and several leading startups and investment firms.

Day One: Smart Packaging, AI Evidence, Cancer Innovation Headline Day

The Summit opens with a look at the emerging “smart packaging” ecosystem—where pharma, device makers, and supply-chain technologists are using embedded sensors and connected platforms to manage product integrity and patient adherence in real time.

AI takes center stage in the afternoon session, which focuses squarely on evidence —not hype. Leaders from One Small Step, PONS, and academic research groups will detail real-world deployments, validation frameworks, and unresolved ethical questions shaping the next phase of AI adoption in clinical settings.

Day Two: Cancer Care and Digital Pharmacy Dominate

Cancer care—long a focus of the Summit—returns with a deliberately expanded lens. The session blends scientific progress with caregiver experience and persistent inequities in clinical trial access, featuring senior voices from Memorial Sloan Kettering and FINN Partners.

Later that day, experts from CVS Health, Mount Sinai, GE Healthcare, and Microsoft dissect the accelerating convergence of digital pharmacy, virtual-first care, and last-mile logistics—an area attracting major investment as health systems look for scalable models to manage chronic disease.

GLP-1s and Strategic Investment Close Out Day Three

The third day’s weight-health symposium reflects one of the fastest-moving sectors in medicine. Leaders from Regeneron and Aetna will examine clinical evidence, distribution challenges, and the widening gap in access as demand for GLP-1 therapies continues to surge.

Day Three: Investments

The final symposium shifts to the deal making, shaping healthcare’s next decade. Investors from Draper VC, Rittenhouse VC, Cardiff Ocean Group, and Keles will highlight where capital is flowing, which technologies are outperforming expectations, and where the next major exits may emerge.

Registration for individual symposia or an all-access pass is now open. Tickets are discounted 20% with the code Summit20.

For more information about the event, including full list of speakers and agenda – click here